| Name | Title | Contact Details |
|---|
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
ODS Companies is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Brighton Health Group is BHPS`s parent company whose approach it is to create an ecosystem in which everyone`s success is contingent upon better health for patients. BHG`s businesses collaborate with physicians, payors and plan sponsors to align the economics with better results, enabling consumers to make better decisions. Combining expertise in healthcare economics with operations drives transformation across the healthcare value chain. BHG aligns financial incentives with quality outcomes and clinical accountability. This formula is building a sustainable business model based on shared rewards between the providers, payors, and health plan sponsors.
Bioclinica is the leader in scientifically-driven services and technology-enabled solutions in clinical research. Clinical trials are complex, and traditional approaches are either monolithic or fragmented. Successful trials require an ability to see key details and uncover hidden insights. Employing our scientifically-driven and technology-enabled approach, Bioclinica brings CLARITY to clinical trials for better decisions. With such clarity comes the insight to help trial sponsors and Clinical Research Organizations (CROs) develop new life-improving therapies more efficiently and safely ─ and with improved quality outcomes. Our scientific, medical, technology and domain expertise is unmatched and spans all major therapeutic areas ─ and the full trial lifecycle, from study protocol, to post-approval. Key offerings include: Medical imaging; Cardiac Safety; Clinical Adjudication; Randomization & Trial Supply Management and Optimization; Electronic and eSource Data Capture; Site Payments and Forecasting; Pharmacovigilance; Trial Management; and Risk-based Monitoring. Additionally, as a true multifaceted partner to trial sponsors and CROs, Bioclinica offers an integrated App xChange partner ecosystem, a global Research Network of investigative sites, Patient Recruitment and Lost to Follow-up Services, and Post-approval Research expertise. Bioclinica and our thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.